Molecular markers such as alterations of the FLT3 or NPM1 gene have become factors of prognostic relevance for patients with cytogenetically normal AML. Mutations of the FLT-3 have been reported to worsen the prognosis in AML. On the other hand they provide a target for a potentially promising new therapeutic approach using the multi-kinase inhibitor sorafenib. 1, 2 A 57-year-old man suffering from AML (FAB M2), with an FLT3-ITD (internal tandem duplication) and a mutated NPM gene, proceeded to allo-SCT after two cycles of conventional chemotherapy with idarubicin (12 mg/m 2 days 1-3) and cytosine-arabinoside (2 Â 2 g/m 2 , days 1, 3, 5 and 7). Marrow smear showed CR after the first induction cycle. The mutations listed above were detected by PCR analysis. The patient was conditioned with TBI (2 Gy), fludarabine 150 mg/m 2 and anti-thymocyte globulin (6 mg/kg), and was transplanted with a non-manipulated graft consisting of 12.3 Â 10 6 CD34 þ cells, collected after mobilisation with G-CSF from an unrelated donor carrying a Cw-mismatch. 3 GVHD prophylaxis was carried out with CsA, mycophenolate mofetil and MTX. Neither a significant leukopenia (o1.0 cells/nl) nor thrombocytes below 20 cells/nl were observed. The early course after SCT was uneventful and the patient was discharged on day þ 21. Donor chimerism in marrow was 100% on day þ 28. The FLT3-ITD mutation, specifically detected in AML blasts, was sequenced and a clone-and patient-specific quantitative real-time PCR with a sensitivity of 10 À5 to À6 was established for detection of minimal residual disease. 4, 5 Relapse of AML was diagnosed few weeks later and immunosuppressive agents were discontinued. On day þ 35, acute GVHD of the skin (third degree) was histologically confirmed and treated with steroids and CsA. A BM puncture on day þ 47 revealed again a CR of AML with 100% donor chimerism. Extracorporal photopheresis was initiated against cGVHD (extensive disease). Unfortunately, a second relapse of AML was detected 8 months after allo-SCT and photopheresis was discontinued. A third remission was achieved with one course of chemotherapy consisting of idarubicine (12 mg/m 2 , days 1-3) plus Ara-C (2 Â 1 g/m 2 , days 1, 3, 5 and 7) and was consolidated with another identical cycle. Sorafenib (400 mg/d.p.o.) was initiated after haematological recovery with full-donor chimerism and chronic GVHD (extensive disease) reoccurred. Figure 1 shows the molecular follow-up: initially, FLT3-ITD þ copy numbers could be reduced by more than five log steps by chemotherapy and after first relapse by transplant-induced GVL effects. However, the third www.nature.com/bmt molecular remission in blood and marrow was finally achieved by therapy with sorafenib in conjunction with a GVL effect, as indicated by relapse of chronic GVHD. 6 Actually, the AML is now in third continuous CR after SCT for 8 months (Figure 1) . A slight increase of specific transcripts occurring in the absence of systemic immunosuppression was treated successfully by doubling the sorafenib dose (Figure 1 ). The patient is doing well (ECOG 0) at 22 months after allogeneic transplantation, and active chronic GVHD is actually restricted to the oral cavity and treated with topical steroids and CsA. The presented case shows that sorafenib in conjunction with GVL effects has the power to improve a clinical remission into a molecular remission after second relapse of a FLT3
þ AML. It must be stated that it is impossible to discriminate the contribution of both compounds, however, the follow-up of minimal residual disease in blood and marrow suggests a synergy of both effects. Earlier remissions have been considerably shorter than the third under sorafenib plus cGVHD, and more intensive and effective treatment of extensive cGVHD after the first relapse with CsA, prednisolone and photopheresis has lead to the second relapse. Presently, cGVHD is well controlled and the patient is still MRD-negative at a sensitivity of 10
À5
in the presence of oral therapy with 2 Â 400 mg sorafenib.
In conclusion, therapy with sorafenib could be an option for patients suffering from relapse of FLT3-ITD þ AML after allogeneic transplantation. A possible synergy with GVL effects needs clarification.
